Greencity Acquisition (GRCYF) 10-K/A26 Jul 212020 FY Annual report (amended)Financial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2020	Mar. 30, 2021
Document and Entity Information [Abstract]
Document Type	10-K/A
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2020
Entity Registrant Name	Greencity Acquisition Corp
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Central Index Key	0001768910
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	true
Trading Symbol	GRCYU
Title of 12(b) Security	Units, each consisting of one Ordinary Share and one Warrant
Security Exchange Name.	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		5,260,000
Entity Voluntary Filers	No
Entity Public Float	$ 41,600,000
Amendment Description	Amendment No. 1

BALANCE SHEETS (As Restated)

BALANCE SHEETS (As Restated) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash	$ 473,945	$ 526
Prepaid expenses and other current assets	125,420
Total Current Assets	599,365	526
Security deposit		4,663
Deferred offering costs		193,089
Marketable securities held in Trust Account	40,615,212
Total Assets	41,214,577	198,278
Current liabilities
Accrued expenses	76,649	289
Accrued offering costs	30,000	3,166
Promissory note - related party	394,590	196,495
Total Current Liabilities	501,239	199,950
Warrant liabilities	2,930,000
Deferred underwriting fee payable	1,000,000
Total Liabilities	4,431,239	199,950
Commitments and Contingencies
Ordinary shares subject to possible redemption, 3,112,463 shares at $10.15 per share	31,783,337
Shareholder's Equity (Deficit)
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Ordinary shares, $0.0001 par value; 100,000,000 shares authorized; 2,147,537 and 1,150,000 shares issued and outstanding (excluding 3,112,463 and no shares subject to possible redemption) at December 31, 2020 and 2019, respectively	213	115
Additional paid-in capital	7,350,047	24,885
Accumulated deficit	(2,350,259)	(26,672)
Total Shareholders' Equity (Deficit)	5,000,001	(1,672)
Total Liabilities and Shareholders' Equity	$ 41,214,577	$ 198,278

BALANCE SHEETS (As Restated) (P

BALANCE SHEETS (As Restated) (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019	Feb. 21, 2019
BALANCE SHEETS (As Restated)
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par or stated value per share	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares, issued	2,129,810	1,150,000
Common stock, shares, outstanding	2,129,810	1,150,000
Ordinary shares subject to possible redemption, shares	3,130,190	0
Redemption price per share	$ 10.15

STATEMENTS OF OPERATIONS (As Re

STATEMENTS OF OPERATIONS (As Restated) - USD ($)	12 Months Ended
STATEMENTS OF OPERATIONS (As Restated) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
STATEMENTS OF OPERATIONS (As Restated)
Operating costs	$ 253,637	$ 22,672
Loss from operations	(253,637)	(22,672)
Other income (expense):
Interest earned on marketable securities held in Trust Account	14,324
Offering costs allocated to warrants	(55,162)
Change in fair value of warrant liabilities	(2,030,000)
Unrealized gain on marketable securities held in Trust Account	888
Other income	(2,069,950)
Net loss	$ (2,323,587)	$ (22,672)
Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption	3,342,495
Basic and diluted weighted average ordinary shares outstanding	1,393,574	857,534
Basic and diluted net loss per ordinary share	$ (1.68)	$ (0.03)

STATEMENTS OF CHANGES IN SHAREH

STATEMENTS OF CHANGES IN SHAREHOLDERS' (DEFICIT) EQUITY (As Restated) - USD ($)	Ordinary SharesIPO	Ordinary SharesPrivate placement	Ordinary Shares	Additional Paid-in CapitalIPO	Additional Paid-in CapitalPrivate placement	Additional Paid-in CapitalUnit Purchase Option	Additional Paid-in Capital	Accumulated DeficitIPO	Accumulated DeficitPrivate placement	Accumulated DeficitUnit Purchase Option	Accumulated Deficit	IPO	Private placement	Unit Purchase Option	Total
Balance at Dec. 31, 2018							$ 25,000				$ (4,000)				$ 21,000
Balance (in shares) at Dec. 31, 2018			1
Issuance of ordinary shares			$ 115				(115)				0
Issuance of ordinary shares (in Shares)			1,149,999
Net loss							0				(22,672)				(22,672)
Balance at Dec. 31, 2019			$ 115				24,885				(26,672)				(1,672)
Balance (in shares) at Dec. 31, 2019			1,150,000
Issuance of ordinary shares	$ 400	$ 26		$ 36,578,097	$ 2,529,974	$ 100		$ 0	$ 0	$ 0		$ 36,578,497	$ 2,530,000	$ 100
Issuance of ordinary shares (in Shares)	4,000,000	260,000										4,000,000	260,000
Forfeiture of Founder Shares (in value)			$ (15)				15				0				15
Forfeiture of Founder Shares (in shares)			(150,000)
Offering costs allocated to warrants															55,162
Ordinary shares subject to possible redemption (in value)			$ (313)				(31,783,024)				0				(31,783,337)
Ordinary shares subject to possible redemption (in shares)			(3,130,190)
Net loss							0				(2,323,587)				(2,323,587)
Balance at Dec. 31, 2020			$ 213				$ 7,350,047				$ (2,350,259)				$ 5,000,001
Balance (in shares) at Dec. 31, 2020			2,129,810

STATEMENTS OF CHANGES IN SHAR_2

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (As Restated) (Parenthetical) - shares	Jul. 28, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
IPO
Issuance of ordinary shares (in Shares)	4,000,000	4,000,000	4,000,000	4,000,000
Private placement
Issuance of ordinary shares (in Shares)	260,000	260,000	260,000	260,000

STATEMENTS OF CASH FLOWS (As Re

STATEMENTS OF CASH FLOWS (As Restated) - USD ($)	12 Months Ended
STATEMENTS OF CASH FLOWS (As Restated) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Cash Flow from Operating Activities:
Net loss	$ (2,323,587)	$ (22,672)
Adjustments to reconcile net loss to net cash used in operating activities
Interest earned on marketable securities held in Trust Account	(14,324)
Unrealized gain on marketable securities held in Trust Account	(888)
Offering costs allocated to warrants	55,162
Change in fair value of warrant liabilities	2,030,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(125,420)
Accrued expenses	76,360	(3,711)
Net cash used in operating activities	(302,697)	(26,383)
Cash Flows from Investing Activities:
Security deposit	4,663	(4,663)
Investment of cash into Trust Account	(40,600,000)
Net cash used in investing activities	(40,595,337)	(4,663)
Cash Flows from Financing Activities:
Proceeds from sale of Units, net of underwriting discounts paid	39,000,000
Proceeds from sale of Placement Units	2,600,000
Proceeds from sale of unit purchase option	100
Proceeds from promissory note - related party	198,095	365,500
Repayment of promissory note- related party		(194,000)
Payment of offering costs	(426,742)	(189,923)
Net cash provided by (used in) financing activities	41,371,453	(18,423)
Net Change in Cash	473,419	(49,469)
Cash - Beginning	526	49,995
Cash - Ending	473,945	526
Non-Cash Investing and Financing Activities:
Initial classification of ordinary shares subject to possible redemption	34,044,655
Change in value of ordinary shares subject to possible redemption	(2,261,318)
Deferred underwriting fee payable	1,000,000
Offering costs included in accrued offering costs	30,000	3,166
Conversion of advance from related party to promissory note - related party		$ 24,995
Forfeiture of Founder Shares	$ (15)

DESCRIPTION OF ORGANIZATION AND

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	12 Months Ended
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	Dec. 31, 2020
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Greencity Acquisition Corporation (the “Company”) is a blank check company incorporated in the Cayman Islands on May 14, 2018. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities (“Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on businesses that have a connection to the Asia market. At December 31, 2020, the Company had not commenced any operations. All activity through December 31, 2020 relates to the Company’s formation and the Initial Public Offering (as defined below). The registration statement for the Company’s Initial Public Offering was declared effective on July 23, 2020. On July 28, 2020, the Company consummated the Initial Public Offering of 4,000,000 units (the “Units” and, with respect to the ordinary shares included in the Units sold, the “Public Shares”), generating gross proceeds of $40,000,000, which is described in Note 3. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 260,000 units (the “Private Units”) at a price of $10.00 per Private Unit in a private placement to Cynthia Management Corporation (the “Sponsor”), generating gross proceeds of $2,600,000, which is described in Note 4. Transaction costs amounted to $2,646,665, consisting of $1,000,000 of underwriting fees, $1,000,000 of deferred underwriting fees and $646,665 of other offering costs. Following the closing of the Initial Public Offering on July 28, 2020, an amount of $40,600,000 ($10.15 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Units was placed in a trust account (the “Trust Account”) invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and sale of the Private Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. NASDAQ rules provide that the Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (less any deferred underwriting commissions and taxes payable on interest earned) at the time of the signing of an agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, if the Company is no longer a foreign private issuer, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination. The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination. If the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from seeking redemption rights with respect to 15% or more of the Public Shares without the Company’s prior written consent. If the Company continues to be a foreign private issuer or if a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, offer such redemption pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.15 per Public Share, subject to increase of up to an additional $0.30 per Public Share in the event that the Sponsor elects to extend the period of time to consummate a Business Combination (see below), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 6). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. The Sponsor and any of the Company’s officers or directors that may hold founder shares (the “initial shareholders”) will agree (a) to vote their founder shares, the ordinary shares included in the Private Units (the “Private Shares”) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination, (b) not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association with respect to the Company’s pre-Business Combination activities prior to the consummation of a Business Combination unless the Company provides dissenting public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment; (c) not to redeem any shares (including the founder shares) and Private Shares into the right to receive cash from the Trust Account in connection with a shareholder vote to approve a Business Combination (or to sell any shares in a tender offer in connection with a Business Combination if the Company does not seek shareholder approval in connection therewith) or a vote to amend the provisions of the Amended and Restated Memorandum and Articles of Association relating to shareholders’ rights of pre-Business Combination activity and (d) that the founder shares and Private Shares shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated. However, the initial shareholders will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination. The Company will have until July 28, 2021 to consummate a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination by July 28, 2021, the Company may extend the period of time to consummate a Business Combination up to nine times, each by an additional month (for a total of 21 months to complete a Business Combination (the “Combination Period”). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $133,334, up to an aggregate of $1,200,000, or $0.30 per Public Share, on or prior to the date of the applicable deadline, for each monthly extension. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable and less interest to pay dissolution expenses up to $50,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00). The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a vendor (other than the Company’s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below (i) $10.15 per share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Risks and Uncertainties On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Liquidity and Going Concern As of December 31, 2020, the Company had $473,945 in its operating bank accounts and working capital of $98,126. Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. To complete a Business Combination, the Company will need to raise additional capital through loans or additional investments from its Sponsor, stockholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern through one year from the date of these financial statements if a Business Combination is not consummated. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

RESTATEMENT OF PREVIOUSLY ISSUE

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	12 Months Ended
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	Dec. 31, 2020
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	NOTE 2. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS The Company previously accounted for its outstanding Public Warrants (as defined in Note 4) and Private Placement Warrants issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities. The warrant agreement governing the warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. In addition, the warrant agreement includes a provision that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of a single class of common shares, all holders of the warrants would be entitled to receive cash for their warrants (the “tender offer provision”). The Company’s management evaluated the warrants under Accounting Standards Codification (“ASC”) Subtopic 815-40, Contracts in Entity’s Own Equity. ASC Section 815-40-15 addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer’s common stock. Under ASC Section 815-40-15, a warrant is not indexed to the issuer’s common stock if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. The Company’s Private Placement Warrants are not indexed to the Company’s common shares in the manner contemplated by ASC Section 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares. In addition, the tender offer provision included in the warrant agreement fails the “classified in shareholders’ equity” criteria as contemplated by ASC Section 815-40-25. As a result of the above, the Company should have classified the warrants as derivative liabilities in its previously issued financial statements. Under this accounting treatment, the Company is required to measure the fair value of the warrants at the end of each reporting period and recognize changes in the fair value from the prior period in the Company’s operating results for the current period. The Company’s accounting for the warrants as components of equity instead of as derivative liabilities did not have any effect on the Company’s previously reported operating expenses or cash. The impact of the restatement on the Company’s financial statements for each respective period is presented below. Balance Sheet as of July 28, 2020 (Audited) As Reported Adjustment As Restated Warrant Liabilities $ — $ 900,000 $ 900,000 Common stock subject to possible redemption 34,944,653 (900,000) 34,044,653 Common stock 197 9 206 Additional paid-in capital 5,033,585 $ 55,153 5,088,738 Accumulated deficit (33,779) (55,162) (88,941) Number of shares subject to possible redemption (88,670) 3,354,153 Balance Sheet as of September 30, 2020 (Unaudited) Warrant Liabilities $ — $ 990,000 $ 990,000 Common stock subject to possible redemption 34,835,933 (990,006) 33,845,927 Common stock 183 10 193 Additional paid-in capital 5,142,319 145,158 5,287,477 Accumulated deficit (142,500) (145,162) (287,662) Number of shares subject to possible redemption 3,431,787 (97,528) 3,334,259 Balance Sheet as of December 31, 2020 (Audited) Warrant Liabilities $ — $ 2,930,000 $ 2,930,000 Common stock subject to possible redemption 34,713,334 (2,929,997) 31,783,337 Common stock 184 29 213 Additional paid-in capital 5,264,917 2,085,130 7,350,047 Accumulated deficit (265,097) (2,085,162) (2,350,259) Number of shares subject to possible redemption 3,418,752 (288,562) 3,130,190 Statement of Operations for the three months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance $ — $ (55,162) $ (55,162) Change in fair value of warrant liabilities — (90,000) (90,000) Net loss (109,200) (145,162) (254,362) Weighted average shares outstanding, basic and diluted 1,577,353 62,648 1,640,001 Basic and diluted net loss per share, ordinary shares (0.07) (0.09) (0.16) Statement of Operations for the nine months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance $ — $ (55,162) $ (55,162) Change in fair value of warrant liabilities — (90,000) (90,000) Net loss (115,828) (145,162) (260,990) Weighted average shares outstanding, basic and diluted 1,193,856 21,035 1,214,891 Basic and diluted net loss per share, ordinary shares (0.10) (0.12) (0.22) Statement of Operations for the year ended December 31, 2020 (Audited) Offering expenses related to warrant issuance $ — $ (55,162) $ (55,162) Change in fair value of warrant liabilities — (2,030,000) (2,030,000) Net loss (238,425) (2,085,162) (2,323,587) Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption 3,436,356 (93,861) 3,342,495 Basic and diluted weighted average ordinary shares outstanding 1,353,312 40,262 1,393,574 Basic and diluted net loss per share, ordinary shares (0.19) (1.49) (1.68) Statement of Cash Flows for the nine months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance $ — $ 55,162 $ 55,162 Change in fair value of warrant liabilities — 90,000 90,000 Net loss (115,828) (145,162) (260,990) Change in value of ordinary shares subject to possible redemption (108,722) (90,006) (198,728) Statement of Cash Flows for the year ended December 31, 2020 (Audited) Offering expenses related to warrant issuance $ — $ 55,162 $ 55,162 Change in fair value of warrant liabilities — 2,030,000 2,030,000 Net loss (238,425) (2,085,162) (2,323,587) Change in value of ordinary shares subject to possible redemption (231,319) (2,029,999) (2,261,318) Statement of Changes in Shareholder’s Equity for the three and nine months ended September 30, 2020 (Unaudited) Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Additional Paid-in Capital $ 37,352,935 $ (774,838) $ 36,578,097 Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Total Shareholder’s (Deficit) Equity 37,353,335 (774,838) 36,578,497 Sale of 260,000 Private Units – Additional Paid-in Capital 2,599,974 (70,000) 2,529,974 Sale of 260,000 Private Units – Total Shareholder’s (Deficit) Equity 2,600,000 (70,000) 2,530,000 Ordinary shares subject to possible redemption – Additional Paid-in Capital (34,835,590) 989,996 (33,845,594) Ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity (34,835,933) 990,006 (33,845,927) Statement of Changes in Shareholder’s Equity for the year ended December 31, 2020 (Audited) Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Additional Paid-in Capital $ 37,352,935 $ (774,838) $ 36,578,097 Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Total Shareholder’s (Deficit) Equity 37,353,335 (774,838) 36,578,497 Sale of 260,000 Private Units – Additional Paid-in Capital 2,599,974 (70,000) 2,529,974 Sale of 260,000 Private Units – Total Shareholder’s (Deficit) Equity 2,600,000 (70,000) 2,530,000 Ordinary shares subject to possible redemption – Additional Paid-in Capital (34,712,992) 2,929,968 (31,783,024) Ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity (34,713,334) 2,929,997 (31,783,337)

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“USGAAP”) and pursuant to the rules and regulations of the SEC. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2020 and 2019. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. Marketable Securities Held in Trust Account At December 31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills. Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering” . Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering. Accordingly, on December 31, 2020, offering costs totaling $2,646,665 consist of $1,000,000 of underwriting fee, $1,000,000 of deferred underwriting fee and $646,665 of other offering costs. The transaction costs were allocated based on the relative fair value basis, compared to the total offering proceeds, between the fair value of the public warrant liabilities and the ordinary shares. Ordinary Shares Subject to Possible Redemption The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheets. Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits as of December 31, 2020 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods presented. Net Loss Per Ordinary Share (Restated) The Company complies with accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” Net income (loss) per ordinary share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period. The Company’s statement of operations includes a presentation of income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the two-class method of income (loss) per share. Net income per ordinary share subject to possible redemption, basic and diluted, is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account, by the weighted average number of ordinary shares subject to possible redemption outstanding since original issuance. Net loss per non-redeemable ordinary share, basic and diluted, is calculated by dividing the net loss, adjusted for income or loss on marketable securities attributable to ordinary shares subject to possible redemption, by the weighted average number of non-redeemable ordinary shares outstanding for the period. Non-redeemable ordinary shares include Founder Shares and non-redeemable ordinary shares as these shares do not have any redemption features. Non-redeemable ordinary shares participate in the income or loss on marketable securities based on non-redeemable ordinary shares’ proportionate interest. Year Ended December 31, 2020 2019 Ordinary shares subject to possible redemption Numerator: Earnings allocable to ordinary shares subject to possible redemption Unrealized gain on marketable securities held in Trust Account 888 — Interest earned and unrealized gains on marketable securities help in Trust Account $ 14,324 — Net loss allocable to ordinary shares subject to possible redemption $ 15,212 $ — Denominator: Weighted Average Ordinary shares subject to possible redemption Basic and diluted weighted average shares outstanding 3,342,495 — Basic and diluted net income per share $ — — Non-Redeemable Ordinary Shares Numerator: Net loss minus Net Earnings Net Loss $ (2,323,587) $ (22,672) Net loss allocable to ordinary shares subject to possible redemption (15,212) — Non-Redeemable Net Loss $ (2,338,799) $ (22,672) Denominator: Weighted Average Non-Redeemable Ordinary Shares Basic and diluted weighted average shares outstanding 1,393,574 857,534 Basic and diluted net loss per ordinary share $ (1.68) $ (0.03) Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying financial statements, primarily due to their short-term nature, not including the warrants. Derivative Financial Instruments We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument is required within 12 months of the balance sheet date. Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.

INITIAL PUBLIC OFFERING

INITIAL PUBLIC OFFERING	12 Months Ended
INITIAL PUBLIC OFFERING	Dec. 31, 2020
INITIAL PUBLIC OFFERING
INITIAL PUBLIC OFFERING	NOTE 4. INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 4,000,000 Units at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and one redeemable warrant (“Public Warrant”). Each Public Warrant will entitle the holder to purchase one-half of one ordinary share at an exercise price of $11.50 per whole share (see Note 7).

PRIVATE PLACEMENT

PRIVATE PLACEMENT	12 Months Ended
PRIVATE PLACEMENT	Dec. 31, 2020
PRIVATE PLACEMENT
PRIVATE PLACEMENT	NOTE 5. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 260,000 Private Units at a price of $10.00 per Private Unit, for an aggregate purchase price of $2,600,000. The proceeds from the Private Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. The Private Units are identical to the Units sold in the Initial Public Offering, except for the private warrants (“Private Warrants”), as described in Note 9. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Units and underlying securities will be worthless.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
RELATED PARTY TRANSACTIONS	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 6. RELATED PARTY TRANSACTIONS Founder Shares In December 2018, the Company received $25,000 for the anticipated issuance of 1,150,000 founder shares to the Sponsor. As of December 31, 2018, one founder share was issued to the Sponsor. The remaining 1,149,999 founder shares were issued to the Sponsor on February 21, 2019. The 1,150,000 founder shares included an aggregate of up to 150,000 shares subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment is not exercised in full or in part, so that the Sponsor will collectively own 20% of the Company’s issued and outstanding shares after the Initial Public Offering. On September 10, 2020, the underwriters’ election to exercise their over-allotment option expired unexercised, resulting in the forfeiture of 150,000 founder shares. Accordingly, there were 1,000,000 Founder Shares issued and outstanding. The initial shareholders have agreed not to transfer, assign or sell any of the founder shares (except to certain permitted transferees) until, with respect to 50% of the founder shares, the earlier of (i) six months after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after a Business Combination, with respect to the remaining 50% of the founder shares, upon six months after the date of the consummation of a Business Combination, or earlier, in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property. Administrative Services Arrangement The Company entered into an agreement whereby, commencing on July 24, 2020, through the earlier of the Company’s consummation of a Business Combination and its liquidation, the Company will pay the Sponsor a total of $10,000 per month for certain general and administrative services, including office space, utilities and administrative services, as the Company may require from time to time. For the year ended December 31, 2020, the Company incurred $50,000 in fees for these services, of which such amount is included within accrued expenses in the accompanying balance sheets. Advance from Related Party As of December 31, 2018, the Sponsor advanced the Company an aggregate of $24,995. The advance was non-interest bearing and due on demand. In February 2019, the advance was converted into a promissory note. As of December 31, 2020 and 2019, there were no advances outstanding. Promissory Note — Related Party On February 21, 2019, the Company issued a non-interest bearing, unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000. On June 30, 2019, the Company amended the promissory note such that the Company may borrow up to an aggregate total principal amount of $500,000 (the “Promissory Note”) and on June 20, 2020, the Company further amended the Promissory Note such that the Promissory Note is payable on the earlier of (i) December 31, 2020 or (ii) the consummation of the Initial Public Offering. In connection with the Promissory Note, the Company converted $24,995 in advances as of December 31, 2018 into amounts outstanding under the Promissory Note. On July 28, 2020, the Company amended the Promissory Note such that it is payable upon the consummation of a Business Combination. At December 31, 2020 and 2019, there was $394,590 and $196,495, respectively, outstanding under the Promissory Note. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Promissory Note but no proceeds held in the Trust Account would be used to repay the Promissory Note. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into additional Private Units at a price of $10.00 per Unit. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Related Party Extension Loans As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination up to nine times, each by an additional month (for a total of 21 months to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $133,334 ($0.033 per Public Share), up to an aggregate of $1,200,000, or $0.30 per Public Share, on or prior to the date of the applicable deadline, for each monthly extension. Any such payments would be made in the form of a loan. The terms of the promissory note to be issued in connection with any such loans have not yet been negotiated. If the Company completes a Business Combination, the Company would repay such loaned amounts out of the proceeds of the Trust Account released to the Company. If the Company does not complete a Business Combination, the Company will not repay such loans. Furthermore, the letter agreement with the initial shareholders contains a provision pursuant to which the Sponsor has agreed to waive its right to be repaid for such loans in the event that the Company does not complete a Business Combination. The Sponsor and its affiliates or designees are not obligated to fund the Trust Account to extend the time for the Company to complete a Business Combination.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2020
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 7. COMMITMENTS AND CONTINGENCIES Registration Rights Pursuant to a registration rights agreement entered into on July 23, 2020, the holders of the founder shares, Private Units (and their underlying securities), the shares underlying the warrants underlying the unit purchase option issued to the underwriters and any Units that may be issued upon conversion of the Working Capital Loans (and underlying securities) are entitled to registration rights. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. Notwithstanding the foregoing, the underwriters may not exercise their demand and “piggyback” registration rights after five (5) and seven (7) years after the effective date of the registration statement and may not exercise their demand rights on more than one occasion. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option to purchase up to 600,000 additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. On September 10, 2020, the underwriters’ election to exercise their over-allotment option expired unexercised. The underwriters were paid a cash underwriting discount of two and one-half percent (2.5%) of the gross proceeds of the Initial Public Offering, or $1,000,000. The underwriters are entitled to a deferred fee of two and one-half percent (2.5%) of the gross proceeds of the Initial Public Offering, or $1,000,000. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
SHAREHOLDERS' EQUITY	Dec. 31, 2020
SHAREHOLDERS' EQUITY
SHAREHOLDERS' EQUITY	NOTE 8. SHAREHOLDERS’ EQUITY Preference Shares — On February 21, 2019, the Company filed an Amended and Restated Memorandum and Articles of Incorporation, pursuant to which the Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. At December 31, 2020 and 2019, there were no preference shares designated, issued or outstanding. Ordinary Shares — On February 21, 2019, the Company filed an Amended and Restated Memorandum and Articles of Incorporation, pursuant to which the Company is authorized to issue 100,000,000 ordinary shares, with a par value of $0.0001 per share. Holders of the ordinary shares are entitled to one vote for each ordinary share. As of December 31, 2020 and 2019, there were 2,129,810 and 1,150,000 ordinary shares issued and outstanding, excluding 3,130,190 and 0 ordinary shares subject to possible redemption, respectively. Unit Purchase Option On July 28, 2020, the Company sold the underwriter (and/or its designees), for $100, an option to purchase up to 240,000 Units exercisable at $11.00 per Unit (or an aggregate exercise price of $2,640,000) commencing on the later of the consummation of a Business Combination and January 28, 2021. The unit purchase option may be exercised for cash or on a cashless basis, at the holder’s option, and expires five years from the effective date of the registration statement related to the Initial Public Offering. The Units issuable upon exercise of the option are identical to those offered in the Initial Public Offering. The Company accounted for the unit purchase option as liability classification. The unit purchase option is valued based on the fair value of the public share estimated at the redemption value plus the fair value of the warrants. These amounts are below the exercise price of the unit purchase option therefore the probability of exercise is low resulting in a de minimus value for the unit purchase option. The option and such units purchased pursuant to the option, as well as the ordinary shares underlying such units, the warrants included in such units, and the shares underlying such warrants, have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA’s NASDAQ Conduct Rules. Additionally, the option may not be sold, transferred, assigned, pledged or hypothecated for a one-year period (including the foregoing 180-day period) following July 28, 2020 except to any underwriter and selected dealer participating in the Initial Public Offering and their bona fide officers or partners. The option grants to holders demand and “piggy-back” rights for periods of five and seven years, respectively, from July 28, 2020 with respect to the registration under the Securities Act of the securities directly and indirectly issuable upon exercise of the option. The Company will bear all fees and expenses attendant to registering the securities, other than underwriting commissions which will be paid for by the holders themselves. The exercise price and number of units issuable upon exercise of the option may be adjusted in certain circumstances including in the event of a stock dividend, or the Company’s recapitalization, reorganization, merger or consolidation. However, the option will not be adjusted for issuances of ordinary shares at a price below its exercise price.

WARRANTS

WARRANTS	12 Months Ended
WARRANTS	Dec. 31, 2020
WARRANTS
WARRANTS	NOTE 9. WARRANTS Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) the consummation of a Business Combination or (b) 12 months from the effective date of the registration statement relating to the Initial Public Offering. No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon the exercise of the Public Warrants is not effective within 60 days, the holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise the Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their Public Warrants on a cashless basis. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation. Redemption of warrants when the price per share of ordinary shares equals or exceeds $16.50. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants (except with respect to the Private Placement Warrants): · in whole and not in part, · at a price of $0.01 per warrant, · upon not less than 30 days’ prior written notice of redemption to each Public Warrant holder, · if, and only if, the reported last sale price of the ordinary shares equal or exceed $16.50 per share, (as adjusted for share splits, share capitalizations, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading day period ending on the third trading day prior to the notice of redemption to Public Warrant holders, and · if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless. In addition, if (x) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of the ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $16.50 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 165% of the higher of the Market Value and the Newly Issued Price. The Private Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Warrants and the ordinary shares issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions and the Private Warrants underlying the Private Units issued to the underwriter may not be exercised after five years from the effective date of the Initial Public Offering. Additionally, the Private Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
FAIR VALUE MEASUREMENTS	Dec. 31, 2020
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	NOTE 10. FAIR VALUE MEASUREMENTS (RESTATED) The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Quoted Prices In Significant Other Significant Other December 31, 2020 Active Markets Observable Inputs Unobservable Inputs Description (Audited) (Level 1) (Level 2) (Level 3) Assets: U.S. Treasury Securities held in Trust Account* $ 40,615,212 $ 40,615,212 $ — $ — Liabilities: Derivative warrant liabilities – Public warrants $ 2,740,000 $ 2,740,000 $ — $ — Derivative warrant liabilities – Private warrants 190,000 — — 190,000 Total fair value $ 2,930,000 $ 2,740,000 $ — $ 190,000 *included in cash and investments held in trust account on the Company’s balance sheet. The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the Balance Sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the Statement of Operations. The Company established the initial fair value of the Public Warrants and Private Warrants on July 28, 2020, the date of the Company’s IPO, using a binomial model for Public Warrants and Black-Scholes model for Private Warrants. Due to the use of quoted prices in an active market (Level 1) to measure the fair value of the Public Warrants, subsequent to initial measurement, the Company had transfer out of Level 3 of $930,000 at September 30, 2020. The key inputs into the binomial model and modified Black-Scholes model were as follows at their measurement dates: December 31, July 28, 2020 September 30, 2020 2020 (Initial (Subsequent (Subsequent measurement) measurement) measurement) Input Share price $ 9.99 $ 9.91 $ 10.08 Risk-free interest rate 0.26 % 0.28 % 0.36 % Volatility 10 % 10 % 20 % Exercise price $ 11.50 $ 11.50 $ 11.50 Warrant life 5 years 5 years 5 years The following table presents the changes in fair value of warrant liabilities: Public Private Total Warrants Warrants Warrants Fair Value at July 28, 2020 $ 830,000 $ 70,000 $ 900,000 Change in fair value of public and private warrants 1,910,000 120,000 2,030,000 Fair Value at December 31, 2020 $ 2,740,000 $ 190,000 $ 2,930,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2020
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 11. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“USGAAP”) and pursuant to the rules and regulations of the SEC.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2020 and 2019.
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.
Marketable Securities Held in Trust Account	Marketable Securities Held in Trust Account At December 31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills.
Offering Costs	Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering” . Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering. Accordingly, on December 31, 2020, offering costs totaling $2,646,665 consist of $1,000,000 of underwriting fee, $1,000,000 of deferred underwriting fee and $646,665 of other offering costs. The transaction costs were allocated based on the relative fair value basis, compared to the total offering proceeds, between the fair value of the public warrant liabilities and the ordinary shares.
Ordinary Shares Subject to Possible Redemption	Ordinary Shares Subject to Possible Redemption The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheets.
Income Taxes	Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits as of December 31, 2020 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods presented.
Net Loss Per Ordinary Share (Restated)	Net Loss Per Ordinary Share (Restated) The Company complies with accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” Net income (loss) per ordinary share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period. The Company’s statement of operations includes a presentation of income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the two-class method of income (loss) per share. Net income per ordinary share subject to possible redemption, basic and diluted, is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account, by the weighted average number of ordinary shares subject to possible redemption outstanding since original issuance. Net loss per non-redeemable ordinary share, basic and diluted, is calculated by dividing the net loss, adjusted for income or loss on marketable securities attributable to ordinary shares subject to possible redemption, by the weighted average number of non-redeemable ordinary shares outstanding for the period. Non-redeemable ordinary shares include Founder Shares and non-redeemable ordinary shares as these shares do not have any redemption features. Non-redeemable ordinary shares participate in the income or loss on marketable securities based on non-redeemable ordinary shares’ proportionate interest. Year Ended December 31, 2020 2019 Ordinary shares subject to possible redemption Numerator: Earnings allocable to ordinary shares subject to possible redemption Unrealized gain on marketable securities held in Trust Account 888 — Interest earned and unrealized gains on marketable securities help in Trust Account $ 14,324 — Net loss allocable to ordinary shares subject to possible redemption $ 15,212 $ — Denominator: Weighted Average Ordinary shares subject to possible redemption Basic and diluted weighted average shares outstanding 3,342,495 — Basic and diluted net income per share $ — — Non-Redeemable Ordinary Shares Numerator: Net loss minus Net Earnings Net Loss $ (2,323,587) $ (22,672) Net loss allocable to ordinary shares subject to possible redemption (15,212) — Non-Redeemable Net Loss $ (2,338,799) $ (22,672) Denominator: Weighted Average Non-Redeemable Ordinary Shares Basic and diluted weighted average shares outstanding 1,393,574 857,534 Basic and diluted net loss per ordinary share $ (1.68) $ (0.03)
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying financial statements, primarily due to their short-term nature, not including the warrants. Derivative Financial Instruments We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument is required within 12 months of the balance sheet date.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.

RESTATEMENT OF PREVIOUSLY ISS_2

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)	12 Months Ended
	Dec. 31, 2020
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
Schedule of restatement on the balance sheets, statements of operations and statements of cash flows	Balance Sheet as of July 28, 2020 (Audited) As Reported Adjustment As Restated Warrant Liabilities $ — $ 900,000 $ 900,000 Common stock subject to possible redemption 34,944,653 (900,000) 34,044,653 Common stock 197 9 206 Additional paid-in capital 5,033,585 $ 55,153 5,088,738 Accumulated deficit (33,779) (55,162) (88,941) Number of shares subject to possible redemption (88,670) 3,354,153 Balance Sheet as of September 30, 2020 (Unaudited) Warrant Liabilities $ — $ 990,000 $ 990,000 Common stock subject to possible redemption 34,835,933 (990,006) 33,845,927 Common stock 183 10 193 Additional paid-in capital 5,142,319 145,158 5,287,477 Accumulated deficit (142,500) (145,162) (287,662) Number of shares subject to possible redemption 3,431,787 (97,528) 3,334,259 Balance Sheet as of December 31, 2020 (Audited) Warrant Liabilities $ — $ 2,930,000 $ 2,930,000 Common stock subject to possible redemption 34,713,334 (2,929,997) 31,783,337 Common stock 184 29 213 Additional paid-in capital 5,264,917 2,085,130 7,350,047 Accumulated deficit (265,097) (2,085,162) (2,350,259) Number of shares subject to possible redemption 3,418,752 (288,562) 3,130,190 Statement of Operations for the three months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance $ — $ (55,162) $ (55,162) Change in fair value of warrant liabilities — (90,000) (90,000) Net loss (109,200) (145,162) (254,362) Weighted average shares outstanding, basic and diluted 1,577,353 62,648 1,640,001 Basic and diluted net loss per share, ordinary shares (0.07) (0.09) (0.16) Statement of Operations for the nine months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance $ — $ (55,162) $ (55,162) Change in fair value of warrant liabilities — (90,000) (90,000) Net loss (115,828) (145,162) (260,990) Weighted average shares outstanding, basic and diluted 1,193,856 21,035 1,214,891 Basic and diluted net loss per share, ordinary shares (0.10) (0.12) (0.22) Statement of Operations for the year ended December 31, 2020 (Audited) Offering expenses related to warrant issuance $ — $ (55,162) $ (55,162) Change in fair value of warrant liabilities — (2,030,000) (2,030,000) Net loss (238,425) (2,085,162) (2,323,587) Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption 3,436,356 (93,861) 3,342,495 Basic and diluted weighted average ordinary shares outstanding 1,353,312 40,262 1,393,574 Basic and diluted net loss per share, ordinary shares (0.19) (1.49) (1.68) Statement of Cash Flows for the nine months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance $ — $ 55,162 $ 55,162 Change in fair value of warrant liabilities — 90,000 90,000 Net loss (115,828) (145,162) (260,990) Change in value of ordinary shares subject to possible redemption (108,722) (90,006) (198,728) Statement of Cash Flows for the year ended December 31, 2020 (Audited) Offering expenses related to warrant issuance $ — $ 55,162 $ 55,162 Change in fair value of warrant liabilities — 2,030,000 2,030,000 Net loss (238,425) (2,085,162) (2,323,587) Change in value of ordinary shares subject to possible redemption (231,319) (2,029,999) (2,261,318) Statement of Changes in Shareholder’s Equity for the three and nine months ended September 30, 2020 (Unaudited) Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Additional Paid-in Capital $ 37,352,935 $ (774,838) $ 36,578,097 Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Total Shareholder’s (Deficit) Equity 37,353,335 (774,838) 36,578,497 Sale of 260,000 Private Units – Additional Paid-in Capital 2,599,974 (70,000) 2,529,974 Sale of 260,000 Private Units – Total Shareholder’s (Deficit) Equity 2,600,000 (70,000) 2,530,000 Ordinary shares subject to possible redemption – Additional Paid-in Capital (34,835,590) 989,996 (33,845,594) Ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity (34,835,933) 990,006 (33,845,927) Statement of Changes in Shareholder’s Equity for the year ended December 31, 2020 (Audited) Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Additional Paid-in Capital $ 37,352,935 $ (774,838) $ 36,578,097 Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Total Shareholder’s (Deficit) Equity 37,353,335 (774,838) 36,578,497 Sale of 260,000 Private Units – Additional Paid-in Capital 2,599,974 (70,000) 2,529,974 Sale of 260,000 Private Units – Total Shareholder’s (Deficit) Equity 2,600,000 (70,000) 2,530,000 Ordinary shares subject to possible redemption – Additional Paid-in Capital (34,712,992) 2,929,968 (31,783,024) Ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity (34,713,334) 2,929,997 (31,783,337)

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of reconciliation of net loss per ordinary share	Year Ended December 31, 2020 2019 Ordinary shares subject to possible redemption Numerator: Earnings allocable to ordinary shares subject to possible redemption Unrealized gain on marketable securities held in Trust Account 888 — Interest earned and unrealized gains on marketable securities help in Trust Account $ 14,324 — Net loss allocable to ordinary shares subject to possible redemption $ 15,212 $ — Denominator: Weighted Average Ordinary shares subject to possible redemption Basic and diluted weighted average shares outstanding 3,342,495 — Basic and diluted net income per share $ — — Non-Redeemable Ordinary Shares Numerator: Net loss minus Net Earnings Net Loss $ (2,323,587) $ (22,672) Net loss allocable to ordinary shares subject to possible redemption (15,212) — Non-Redeemable Net Loss $ (2,338,799) $ (22,672) Denominator: Weighted Average Non-Redeemable Ordinary Shares Basic and diluted weighted average shares outstanding 1,393,574 857,534 Basic and diluted net loss per ordinary share $ (1.68) $ (0.03)

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Dec. 31, 2020
FAIR VALUE MEASUREMENTS
Schedule of Company's asset measured at fair value on a recurring basis	The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Quoted Prices In Significant Other Significant Other December 31, 2020 Active Markets Observable Inputs Unobservable Inputs Description (Audited) (Level 1) (Level 2) (Level 3) Assets: U.S. Treasury Securities held in Trust Account* $ 40,615,212 $ 40,615,212 $ — $ — Liabilities: Derivative warrant liabilities – Public warrants $ 2,740,000 $ 2,740,000 $ — $ — Derivative warrant liabilities – Private warrants 190,000 — — 190,000 Total fair value $ 2,930,000 $ 2,740,000 $ — $ 190,000 *included in cash and investments held in trust account on the Company’s balance sheet.
Schedule of initial measurement of key inputs	December 31, July 28, 2020 September 30, 2020 2020 (Initial (Subsequent (Subsequent measurement) measurement) measurement) Input Share price $ 9.99 $ 9.91 $ 10.08 Risk-free interest rate 0.26 % 0.28 % 0.36 % Volatility 10 % 10 % 20 % Exercise price $ 11.50 $ 11.50 $ 11.50 Warrant life 5 years 5 years 5 years
Summary of the changes in the fair value of the liabilities, a Level 1 liability, measured on a recurring basis	Public Private Total Warrants Warrants Warrants Fair Value at July 28, 2020 $ 830,000 $ 70,000 $ 900,000 Change in fair value of public and private warrants 1,910,000 120,000 2,030,000 Fair Value at December 31, 2020 $ 2,740,000 $ 190,000 $ 2,930,000

DESCRIPTION OF ORGANIZATION A_2

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details) - USD ($)	Jul. 28, 2020	Feb. 21, 2019	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Gross proceeds from issuance of warrants					$ 2,600,000
Deferred underwriting fee					1,000,000
Cash					473,945	$ 49,995	$ 526
Working capital					$ 98,126
Share redemption (as a percent)					15.00%
Redemption price per share					$ 10.15
Related party transaction, extension Period of time to consummate a Business Combination					21 months
Related party transaction, Amount deposited into trust account by sponsor					$ 133,334
Related party transaction proceeds from exercise of shares					$ 1,200,000
Percentage of shares of stock the Company is obligated to redeem without consummating a business combination					100.00%
Operating bank accounts					$ 473,945
Dissolution expenses					$ 50,000
Maximum
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Redemption price per share					$ 0.30
Sponsor
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock issued (in shares)		1,149,999				1
Proceeds from issuance IPO	$ 40,600,000
Ownership interest to be acquired on post-transaction company					50.00%
Shares issued price per share	$ 10.15
Fair value on assets held In trust (as a percent)					80.00%
Business combination limit on net tangible assets					$ 5,000,001
IPO
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock issued (in shares)	4,000,000		4,000,000	4,000,000	4,000,000
Proceeds from issuance IPO	$ 40,000,000
Exercise price of warrants or rights					$ 11.50
Transaction cost	2,646,665
Underwriting fees	1,000,000
Deferred underwriting fee	1,000,000
Other offering costs	$ 646,665
Shares issued price per share					$ 10
Private placement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock issued (in shares)	260,000		260,000	260,000	260,000
Gross proceeds from issuance of warrants	$ 2,600,000
Shares issued price per share	$ 10				$ 10

RESTATEMENT OF PREVIOUSLY ISS_3

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - BALANCE SHEETS (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020	Jul. 28, 2020	Dec. 31, 2019	Dec. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities	$ 2,930,000		$ 900,000
Ordinary shares subject to possible redemption (in value)	31,783,337
Common stock value	213			$ 115
Additional paid-in capital	7,350,047			24,885
Accumulated deficit	(2,350,259)			(26,672)
Total Stockholders' Equity	$ 5,000,001			$ (1,672)	$ 21,000
Ordinary shares subject to possible redemption (in shares)	3,130,190			0
Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities	$ 2,930,000	$ 990,000	900,000
Additional paid-in capital	7,350,047	5,287,477	5,088,738
Accumulated deficit	$ (2,350,259)	$ (287,662)	$ (88,941)
Ordinary shares subject to possible redemption (in shares)	3,130,190	3,334,259	3,354,153
Class A common stock subject to possible redemption \| Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	$ 31,783,337	$ 33,845,927	$ 34,044,653
Class A common stock \| Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock value	213	193	206
As Reported \| Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Additional paid-in capital	5,264,917	5,142,319	5,033,585
Accumulated deficit	$ (265,097)	$ (142,500)	$ (33,779)
Ordinary shares subject to possible redemption (in shares)	3,418,752	3,431,787	3,442,823
As Reported \| Class A common stock subject to possible redemption \| Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	$ 34,713,334	$ 34,835,933	$ 34,944,653
As Reported \| Class A common stock \| Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock value	184	183	197
Adjustment \| Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities	2,930,000	990,000	900,000
Additional paid-in capital	2,085,130	145,158	55,153
Accumulated deficit	$ (2,085,162)	$ (145,162)	$ (55,162)
Ordinary shares subject to possible redemption (in shares)	(288,562)	(97,528)	(88,670)
Adjustment \| Class A common stock subject to possible redemption \| Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	$ (2,929,997)	$ (990,006)	$ (900,000)
Adjustment \| Class A common stock \| Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock value	$ 29	$ 10	$ 9

RESTATEMENT OF PREVIOUSLY ISS_4

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - STATEMENTS OF OPERATIONS (Details) - USD ($)	3 Months Ended	5 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance				$ (55,162)
Change in fair value of warrant liabilities		$ (2,030,000)		(2,030,000)
Net loss				$ (2,323,587)	$ (22,672)
Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption				3,342,495
Basic and diluted weighted average ordinary shares outstanding				1,393,574	857,534
Basic and diluted net loss per ordinary share				$ (1.68)	$ (0.03)
Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance	$ (55,162)		$ (55,162)	$ (55,162)
Change in fair value of warrant liabilities	(90,000)		(90,000)	(2,030,000)
Net loss	$ (254,362)		$ (260,990)	$ (2,323,587)
Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption				(3,342,495)
Basic and diluted weighted average ordinary shares outstanding	1,640,001		1,214,891	1,393,574
Basic and diluted net loss per ordinary share	$ (0.16)		$ (0.22)	$ (1.68)
Restatement of the Company's Financial Statements \| As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (109,200)		$ (115,828)	$ (238,425)
Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption				(3,436,356)
Basic and diluted weighted average ordinary shares outstanding	1,577,353		1,193,856	1,353,312
Basic and diluted net loss per ordinary share	$ (0.07)		$ (0.10)	$ (0.19)
Restatement of the Company's Financial Statements \| Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance	$ (55,162)		$ (55,162)	$ (55,162)
Change in fair value of warrant liabilities	(90,000)		(90,000)	(2,030,000)
Net loss	$ (145,162)		$ (145,162)	$ (2,085,162)
Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption				93,861
Basic and diluted weighted average ordinary shares outstanding	62,648		21,035	40,262
Basic and diluted net loss per ordinary share	$ (0.09)		$ (0.12)	$ (1.49)

RESTATEMENT OF PREVIOUSLY ISS_5

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - STATEMENTS OF CASH FLOWS (Details) - USD ($)	3 Months Ended	5 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance				$ 55,162
Change in fair value of warrant liabilities		$ 2,030,000		2,030,000
Net loss				(2,323,587)	$ (22,672)
Change in value of ordinary shares subject to possible redemption				(2,261,318)
Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance	$ 55,162		$ 55,162	55,162
Change in fair value of warrant liabilities	90,000		90,000	2,030,000
Net loss	(254,362)		(260,990)	(2,323,587)
Change in value of ordinary shares subject to possible redemption			(198,728)	(2,261,318)
Restatement of the Company's Financial Statements \| As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(109,200)		(115,828)	(238,425)
Change in value of ordinary shares subject to possible redemption			(108,722)	(231,319)
Restatement of the Company's Financial Statements \| Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance	55,162		55,162	55,162
Change in fair value of warrant liabilities	90,000		90,000	2,030,000
Net loss	$ (145,162)		(145,162)	(2,085,162)
Change in value of ordinary shares subject to possible redemption			$ (90,006)	$ (2,029,999)

RESTATEMENT OF PREVIOUSLY ISS_6

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)			$ 31,783,337
IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares			36,578,497
Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares			2,530,000
Additional Paid-in Capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares				$ (115)
Ordinary shares subject to possible redemption (in value)			31,783,024
Additional Paid-in Capital \| IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares			36,578,097
Additional Paid-in Capital \| Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares			2,529,974
Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	$ (33,845,927)	$ (33,845,927)	(31,783,337)
Restatement of the Company's Financial Statements \| IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	36,578,497	36,578,497	36,578,497
Restatement of the Company's Financial Statements \| Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	2,530,000	2,530,000	2,530,000
Restatement of the Company's Financial Statements \| Additional Paid-in Capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	(33,845,594)	(33,845,594)	(31,783,024)
Restatement of the Company's Financial Statements \| Additional Paid-in Capital \| IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	36,578,097	36,578,097	36,578,097
Restatement of the Company's Financial Statements \| Additional Paid-in Capital \| Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	2,529,974	2,529,974	2,529,974
Restatement of the Company's Financial Statements \| As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	(34,835,933)	(34,835,933)	(34,713,334)
Restatement of the Company's Financial Statements \| As Reported \| IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	37,353,335	37,353,335	37,353,335
Restatement of the Company's Financial Statements \| As Reported \| Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	2,600,000	2,600,000	2,600,000
Restatement of the Company's Financial Statements \| As Reported \| Additional Paid-in Capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	(34,835,590)	(34,835,590)	(34,712,992)
Restatement of the Company's Financial Statements \| As Reported \| Additional Paid-in Capital \| IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	37,352,935	37,352,935	37,352,935
Restatement of the Company's Financial Statements \| As Reported \| Additional Paid-in Capital \| Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	2,599,974	2,599,974	2,599,974
Restatement of the Company's Financial Statements \| Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	990,006	990,006	2,929,997
Restatement of the Company's Financial Statements \| Adjustment \| IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	(774,838)	(774,838)	(774,838)
Restatement of the Company's Financial Statements \| Adjustment \| Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	(70,000)	(70,000)	(70,000)
Restatement of the Company's Financial Statements \| Adjustment \| Additional Paid-in Capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	989,996	989,996	2,929,968
Restatement of the Company's Financial Statements \| Adjustment \| Additional Paid-in Capital \| IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	(774,838)	(774,838)	(774,838)
Restatement of the Company's Financial Statements \| Adjustment \| Additional Paid-in Capital \| Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares	$ (70,000)	$ (70,000)	$ (70,000)

RESTATEMENT OF PREVIOUSLY ISS_7

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (Parenthetical) (Details) - shares	Jul. 28, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares (in Shares)	4,000,000	4,000,000	4,000,000	4,000,000
Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares (in Shares)	260,000	260,000	260,000	260,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Initial public offering, offering costs	$ 2,646,665
Underwriting fee	1,000,000
Deferred underwriting fee	1,000,000
Other offering cost	646,665
Unrecognized Tax Benefits	0
Unrecognized tax benefits, interest and penalty accrued	0
Tax provision	0
Federal depository insurance coverage	$ 250,000

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Net Loss Per Ordinary Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Numerator: Earnings allocable to ordinary shares subject to possible redemption
Unrealized gain on marketable securities held in Trust Account	$ 888
Interest earned and unrealized gains on marketable securities held in Trust Account	14,324
Net loss allocable to ordinary shares subject to possible redemption	$ 15,212
Denominator: Weighted Average Ordinary shares subject to possible redemption
Basic and diluted weighted average shares outstanding	3,342,495
Numerator: Net loss minus Net Earnings
Net loss	$ (2,323,587)	$ (22,672)
Net loss allocable to ordinary shares subject to possible redemption	(15,212)
Non-Redeemable Net Loss	$ (2,338,799)	$ (22,672)
Denominator: Weighted Average Non-Redeemable Ordinary Shares
Weighted average shares outstanding, basic and diluted	1,393,574	857,534
Basic and diluted net loss per ordinary share	$ (1.68)	$ (0.03)

INITIAL PUBLIC OFFERING - Addit

INITIAL PUBLIC OFFERING - Additional Information (Details) - IPO - $ / shares	Jul. 28, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Issuance of ordinary shares (in Shares)	4,000,000	4,000,000	4,000,000	4,000,000
Unit price				$ 10
Number of ordinary shares per unit				1
Number of public warrants per unit				1
Warrants exercise ratio				0.5
Warrants exercise price				$ 11.50

PRIVATE PLACEMENT - Additional

PRIVATE PLACEMENT - Additional Information (Details) - USD ($)	Jul. 28, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Ordinary Shares
Subsidiary, Sale of Stock [Line Items]
Number of common stock issued (in shares)					1,149,999
Sale of unit (in value)					$ 115
Private placement
Subsidiary, Sale of Stock [Line Items]
Number of common stock issued (in shares)	260,000	260,000	260,000	260,000
Aggregate purchase price				$ 2,600,000
Shares issued price per share	$ 10			$ 10
Sale of unit (in value)				$ 2,530,000
Private placement \| Ordinary Shares
Subsidiary, Sale of Stock [Line Items]
Number of common stock issued (in shares)				260,000
Sale of unit (in value)				$ 26

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Feb. 21, 2019	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019	Jun. 30, 2019
Related Party Transaction [Line Items]
Common stock, shares, issued			2,129,810		1,150,000
Common stock, shares, outstanding			2,129,810		1,150,000
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination		30 days
Due to related parties			$ 0		$ 0
Due to related parties			394,590		196,495
General and administrative services expense per month			10,000
Related party transaction, Converted notes upon consummation of a Business Combination			$ 1,500,000
Related party transaction, Converted notes Price per share upon consummation of a Business Combination			$ 10
Related party transaction general and administrative services expenses			$ 50,000
Related party transaction, extension Period of time to consummate a Business Combination			21 months
Related party transaction, Amount deposited into trust account by sponsor			$ 133,334
Related Party Transaction, Proceeds From Exercise Of Shares			$ 1,200,000
Public Price Per share, underwriters' over-allotment option is exercised in full			$ 0.033
Related Party Loans
Related Party Transaction [Line Items]
Related party transaction, Amount deposited into trust account by sponsor			$ 133,334
Related Party Loans \| Working Capital Loans Warrant
Related Party Transaction [Line Items]
Public Price Per share, underwriters' over-allotment option is exercised in full on or prior to the date of the applicable deadline			0.30%
Sponsor
Related Party Transaction [Line Items]
Proceeds from issuance of shares		$ 25,000
Anticipated issuance of founder shares to the Sponsor				1,150,000
Number of common stock issued (in shares)	1,149,999			1
Weighted average number of shares, common stock subject to forfeiture		150,000		150,000
Shares owned by sponsor (in percentage)		20.00%
Common stock, shares, issued			1,000,000
Common stock, shares, outstanding			1,000,000
Percentage of Shares agreed not to transfer, assign or sell		50.00%
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)		$ 12.50
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination		20 days
Percentage of transfer of remaining founder shares based on certain exceptions		50.00%
Due to related parties		$ 24,995		$ 24,995
Unsecured promissory note
Related Party Transaction [Line Items]
Due to related parties					$ 196,495
Borrowings principal amount	$ 300,000
Due to related parties			$ 394,590
Unsecured promissory note \| Maximum
Related Party Transaction [Line Items]
Borrowings principal amount						$ 500,000
Unsecured promissory note \| Sponsor
Related Party Transaction [Line Items]
Due to related parties		$ 24,995		$ 24,995

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - Underwriting Agreement	12 Months Ended
	Dec. 31, 2020USD ($)shares
COMMITMENTS AND CONTINGENCIES
Underwriter purchase option limitation period	45 days
Underwriter commission (in percentage)	2.50%
Proceeds from issuance of shares to underwriters \| $	$ 1,000,000
Over Allotment Option
COMMITMENTS AND CONTINGENCIES
Number of common stock issued (in shares) \| shares	600,000

SHAREHOLDER'S EQUITY - Addition

SHAREHOLDER'S EQUITY - Additional Information (Details)	12 Months Ended
SHAREHOLDER'S EQUITY - Additional Information (Details)	Dec. 31, 2020USD ($)Vote$ / sharesshares	Jul. 28, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Feb. 21, 2019$ / sharesshares
Class of Stock [Line Items]
Preferred stock, shares authorized	1,000,000		1,000,000	1,000,000
Preferred stock, par or stated value per share \| $ / shares	$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
Common stock, shares authorized	100,000,000		100,000,000	100,000,000
Common stock, par or stated value per share \| $ / shares	$ 0.0001		$ 0.0001	$ 0.0001
Ordinary shares subject to possible redemption, shares	3,130,190		0
Number of votes per share \| Vote	1
Common stock, shares, issued	2,129,810		1,150,000
Common stock, shares, outstanding	2,129,810		1,150,000
Common stock value \| $	$ 213		$ 115
Ordinary Shares
Class of Stock [Line Items]
Ordinary shares subject to possible redemption, shares	3,130,190		0
Common stock, shares, issued	2,129,810		1,150,000
Common stock, shares, outstanding	2,129,810		1,150,000
Unit Purchase Option
Class of Stock [Line Items]
Common stock, shares, issued		240,000
Underwriter Commission \| $		$ 100
Unit price \| $ / shares		$ 11
Common stock value \| $		$ 2,640,000

WARRANTS - Warrants activity (D

WARRANTS - Warrants activity (Details)	12 Months Ended
WARRANTS - Warrants activity (Details)	Dec. 31, 2020$ / shares
Class of Stock [Line Items]
Warrants redemption price	$ 0.01
Sale price of the ordinary shares	$ 16.50
Minimum
Class of Stock [Line Items]
Written notice of redemption to each Public Warrant holder	20 days
Maximum
Class of Stock [Line Items]
Written notice of redemption to each Public Warrant holder	30 days
Closing of business combination
Class of Stock [Line Items]
Unit price	$ 9.20
Percentage of gross proceeds on additional issuance of shares	60.00%
Period In Which Private Warrants will not Be Transferable	30 days
Market value below $ 9.20 \| Closing of business combination
Class of Stock [Line Items]
Exercise price of the warrants will be adjusted of the higher of the market value (in percentage)	115.00%
Market value $ 16.50 \| Closing of business combination
Class of Stock [Line Items]
Exercise price of the warrants will be adjusted of the higher of the market value (in percentage)	165.00%
Warrants
Class of Stock [Line Items]
Sale price of the ordinary shares	$ 16.50

FAIR VALUE MEASUREMENTS - Fair

FAIR VALUE MEASUREMENTS - Fair Value (Details) - USD ($)	Dec. 31, 2020	Jul. 28, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	$ 2,930,000	$ 900,000
Fair Value, Recurring [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	2,930,000
Fair Value, Recurring [Member] \| Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	2,740,000
Fair Value, Recurring [Member] \| Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	190,000
Fair Value, Recurring [Member] \| US Treasury Securities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities held in Trust Account	40,615,212
Fair Value, Recurring [Member] \| US Treasury Securities [Member] \| Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities held in Trust Account	40,615,212
Private Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	190,000	70,000
Private Placement Warrants \| Fair Value, Recurring [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	190,000
Private Placement Warrants \| Fair Value, Recurring [Member] \| Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	190,000
Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	2,740,000	$ 830,000
Public Warrants \| Fair Value, Recurring [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	2,740,000
Public Warrants \| Fair Value, Recurring [Member] \| Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	$ 2,740,000

FAIR VALUE MEASUREMENTS - Initi

FAIR VALUE MEASUREMENTS - Initial Measurement (Details)	Dec. 31, 2020	Sep. 30, 2020	Jul. 28, 2020
Share price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Input	10.08	9.91	9.99
Risk free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Input	0.36	0.28	0.26
Volatility rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Input	20	10	10
Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Input	11.50	11.50	11.50
Expected term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Input	5	5	5

FAIR VALUE MEASUREMENTS - Addit

FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($)	5 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2020	Jul. 28, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	$ 2,930,000		$ 2,930,000	$ 900,000
Change in fair value of warrant liabilities	2,030,000		2,030,000
Fair value transfer out of level 3		$ 930,000
Private Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	190,000		190,000	70,000
Change in fair value of warrant liabilities	120,000
Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	2,740,000		$ 2,740,000	$ 830,000
Change in fair value of warrant liabilities	$ 1,910,000